Market Overview

UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

Share:
Related BMRN
Baird Downgrades BioMarin Pharmaceutical To Neutral
Benzinga's Volume Movers
Catabasis Up on Fast Track Status for DMD Drug CAT-1004 - Analyst Blog (Zacks)

Stifel Nicolaus upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Hold to Buy and announced a $67.00 price target.

Stifel Nicolaus commented, "We believe anticipation around a YE13 GALNS launch provides a tangible floor in valuation near-term and are increasingly comfortable with PEG-PAL-associated value longer-term. While acknowledging visibility into BMN-701 expansion cohort data remains limited, we believe the pipeline provides multiple additional sources of optionality to drive upside in FY13. We believe the company represents an attractive acquisition candidate near-term while also being one of the few (if any) names that seemingly has a sustainable pathway in place to independently achieve large-cap status longer-term."

BioMarin Pharmaceutical closed at $54.08 on Friday.

Latest Ratings for BMRN

DateFirmActionFromTo
Jun 2015BairdDowngradesOutperformNeutral
Jun 2015BarclaysMaintainsOverweight
Jun 2015Piper JaffrayReiteratesOverweight

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (BMRN)

Around the Web, We're Loving...

Get Benzinga's Newsletters